

# Jessica Cusato

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8127917/jessica-cusato-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

128  
papers

1,795  
citations

24  
h-index

35  
g-index

137  
ext. papers

2,200  
ext. citations

4.6  
avg, IF

4.93  
L-index

#	Paper	IF	Citations
128	25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	236
127	A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2011</b> , 54, 779-88	3.5	55
126	HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2012</b> , 59, 109-16	3.5	53
125	Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 2976-8	5.9	53
124	LC-MS application for therapeutic drug monitoring in alternative matrices. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2019</b> , 166, 40-51	3.5	47
123	Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients. <i>American Journal of Obstetrics and Gynecology</i> , <b>2021</b> , 224, 391.e1-391.e7	6.4	45
122	Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 1772-1777	5.1	41
121	Cannabinoids concentration variability in cannabis olive oil galenic preparations. <i>Journal of Pharmacy and Pharmacology</i> , <b>2018</b> , 70, 143-149	4.8	40
120	Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associated anemia in patients receiving standard anti-HCV treatment. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 165-70	3.2	37
119	Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 3061-6	5.1	34
118	Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. <i>Aids</i> , <b>2012</b> , 26, 1529-33	3.5	33
117	UHPLC-MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2016</b> , 129, 535-541	3.5	31
116	Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D. <i>Liver International</i> , <b>2013</b> , 33, 580-5	7.9	31
115	The "scar" of a pandemic: Cumulative incidence of COVID-19 during the first trimester of pregnancy. <i>Journal of Medical Virology</i> , <b>2021</b> , 93, 537-540	19.7	31
114	Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2013</b> , 936, 42-7	3.2	30
113	Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 2645-9	5.1	30
112	Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 722-8	3.2	30

111	Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 74, 134-40	3.8	29
110	Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. <i>Pharmacogenetics and Genomics</i> , <b>2013</b> , 23, 293-300	1.9	29
109	Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 850-857	3.4	25
108	Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. <i>Antiviral Research</i> , <b>2013</b> , 100, 114-9	10.8	25
107	Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. <i>Antiviral Research</i> , <b>2014</b> , 102, 35-43	10.8	25
106	Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. <i>Hepatology</i> , <b>2011</b> , 54, 2278-9	11.2	25
105	UHPLC-MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2017</b> , 142, 279-285	3.5	24
104	High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 241-5	5.1	24
103	Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2012</b> , 66, 376-80	3.5	24
102	Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 260-3	3.4	23
101	Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 197-203	3.8	23
100	Efavirenz pharmacogenetics in a cohort of Italian patients. <i>International Journal of Antimicrobial Agents</i> , <b>2016</b> , 47, 117-23	14.3	21
99	The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon. <i>Journal of Infection</i> , <b>2014</b> , 69, 81-7	18.9	20
98	Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 318-27	3.4	19
97	Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. <i>Clinical Pharmacokinetics</i> , <b>2017</b> , 56, 355-369	6.2	19
96	Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 2535-2543	3.8	19
95	Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. <i>Pharmacogenomics Journal</i> , <b>2016</b> , 16, 514-518	3.5	18
94	Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 907-10	5.1	18

93	Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. <i>Antiviral Therapy</i> , <b>2015</b> , 20, 335-41	1.6	17
92	Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. <i>Pharmacogenomics Journal</i> , <b>2015</b> , 15, 263-71	3.5	16
91	UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2016</b> , 118, 64-69	3.5	16
90	Pharmacogenetics of ribavirin-induced anemia in HCV patients. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 925-41	2.6	16
89	SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 1035-1043	5.1	15
88	Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 3096-9	5.1	14
87	A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2017</b> , 145, 718-724	3.5	14
86	Role of pharmacogenetics on deferasirox AUC and efficacy. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 561-72	2.6	13
85	Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2017</b> , 44, 1083-1088	3	13
84	Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. <i>Biomedicine and Pharmacotherapy</i> , <b>2015</b> , 69, 47-55	7.5	12
83	ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. <i>Biomedicine and Pharmacotherapy</i> , <b>2015</b> , 69, 63-9	7.5	12
82	Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. <i>Antiviral Research</i> , <b>2014</b> , 109, 7-14	10.8	12
81	Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection. <i>Biomedicines</i> , <b>2017</b> , 5,	4.8	12
80	Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment. <i>Aids</i> , <b>2016</b> , 30, 915-20	3.5	11
79	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 539-554	2.6	10
78	VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. <i>Pharmacogenetics and Genomics</i> , <b>2015</b> , 25, 164-72	1.9	10
77	Pharmacogenetic of voriconazole antifungal agent in pediatric patients. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 913-925	2.6	10
76	Ultra performance liquid chromatography PDA method for determination of tigecycline in human plasma. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 853-8	3.2	10

75	Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. <i>International Journal of Pharmaceutics</i> , <b>2016</b> , 497, 287-92	6.5	9
74	Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. <i>Infection</i> , <b>2017</b> , 45, 103-106	5.8	9
73	Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. <i>Antiviral Research</i> , <b>2014</b> , 106, 105-10	10.8	9
72	Longitudinal analysis of antibody response following SARS-CoV-2 infection in pregnancy: From the first trimester to delivery. <i>Journal of Reproductive Immunology</i> , <b>2021</b> , 144, 103285	4.2	9
71	Deferasirox pharmacokinetic and toxicity correlation in ß-thalassaemia major treatment. <i>Journal of Pharmacy and Pharmacology</i> , <b>2016</b> , 68, 1417-1421	4.8	9
70	Precision medicine for HIV: where are we?. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 145-165	2.6	9
69	Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. <i>International Journal of Antimicrobial Agents</i> , <b>2015</b> , 45, 657-61	14.3	8
68	Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , <b>2015</b> , 18, 171-6	3.4	8
67	Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 307-8	5.1	8
66	Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia. <i>Pharmacogenetics and Genomics</i> , <b>2016</b> , 26, 307-10	1.9	8
65	Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon. <i>Antiviral Research</i> , <b>2016</b> , 136, 32-36	10.8	8
64	Deferasirox AUC efficacy cutoff and role of pharmacogenetics. <i>European Journal of Clinical Pharmacology</i> , <b>2016</b> , 72, 1155-7	2.8	8
63	The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 450-457	6.1	7
62	Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment. <i>Archives of Virology</i> , <b>2015</b> , 160, 2009-17	2.6	7
61	Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 81, 615-620	3.5	7
60	Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 633-4	13.4	7
59	Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 1659-1664	5.1	6
58	Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. <i>Journal of Clinical Pharmacology</i> , <b>2018</b> , 58, 1550-1556	2.9	6

57	Influence of ABCB11 and HNF4B genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 2846-2849	5.1	6
56	Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma. <i>Journal of Pharmacy and Pharmacology</i> , <b>2017</b> , 69, 1524-1530	4.8	6
55	Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C. <i>Infection, Genetics and Evolution</i> , <b>2017</b> , 53, 195-198	4.5	6
54	Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B. <i>International Journal of Antimicrobial Agents</i> , <b>2016</b> , 48, 324-7	14.3	6
53	A Common mdr1 Gene Polymorphism is Associated With Changes in Linezolid Clearance. <i>Therapeutic Drug Monitoring</i> , <b>2018</b> , 40, 602-609	3.2	6
52	Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 651-661	2.6	5
51	Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 865-880	2.6	5
50	Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. <i>Archives of Virology</i> , <b>2018</b> , 163, 961-967	2.6	5
49	Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage. <i>Antiviral Research</i> , <b>2015</b> , 116, 45-7	10.8	5
48	Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 604-6	3.2	5
47	Cerebral white matter Hyperintensities in HIV-positive patients. <i>Brain Imaging and Behavior</i> , <b>2020</b> , 14, 10-18	4.1	5
46	Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes. <i>Pharmacogenomics Journal</i> , <b>2018</b> , 18, 506-515	3.5	5
45	High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 135-138	5.1	5
44	Deferasirox pharmacokinetic evaluation in Thalassemia paediatric patients. <i>Journal of Pharmacy and Pharmacology</i> , <b>2017</b> , 69, 525-528	4.8	4
43	The role of ITPA and ribavirin transporter genes polymorphisms in prediction of ribavirin-induced anaemia in chronic hepatitis C Egyptian patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2017</b> , 44, 965-968	3	4
42	Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , <b>2019</b> , 11,	6.6	4
41	Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia. <i>Journal of NeuroVirology</i> , <b>2018</b> , 24, 132-136	3.9	4
40	Obstetric and neonatal outcomes after SARS-CoV-2 infection in the first trimester of pregnancy: A prospective comparative study. <i>Journal of Obstetrics and Gynaecology Research</i> , <b>2021</b> ,	1.9	4

39	The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. <i>Pharmacogenomics Journal</i> , <b>2019</b> , 19, 417-427	3.5	4
38	Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children. <i>Pharmacogenetics and Genomics</i> , <b>2018</b> , 28, 17-22	1.9	4
37	Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study. <i>Infection, Genetics and Evolution</i> , <b>2017</b> , 51, 167-172	4.5	3
36	Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	3
35	Trend of 25-hydroxycholesterol and 27-hydroxycholesterol plasma levels in patients affected by active chronic hepatitis B virus infection and inactive carriers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2021</b> , 210, 105854	5.1	3
34	Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. <i>Pharmacogenomics Journal</i> , <b>2020</b> , 20, 202-212	3.5	3
33	Prenatal Biochemical and Ultrasound Markers in COVID-19 Pregnant Patients: A Prospective Case-Control Study. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	3
32	Clinical relevance of deferasirox trough levels in $\beta$ -thalassemia patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2018</b> , 45, 213-216	3	3
31	A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples. <i>Journal of Pharmacological and Toxicological Methods</i> , <b>2018</b> , 94, 29-35	1.7	3
30	Wastewater-based SARS-CoV-2 environmental monitoring for Piedmont, Italy. <i>Environmental Research</i> , <b>2022</b> , 203, 111901	7.9	3
29	Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients. <i>Infection, Genetics and Evolution</i> , <b>2018</b> , 60, 42-47	4.5	2
28	Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 373-377	1.6	2
27	Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. <i>Pharmaceuticals</i> , <b>2020</b> , 14,	5.2	2
26	Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> ,	3.8	2
25	Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous $\beta$ -thalassaemia. <i>Biomedicine and Pharmacotherapy</i> , <b>2016</b> , 84, 1510-1512	7.5	2
24	Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 89-102	6.2	2
23	Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis. <i>European Addiction Research</i> , <b>2018</b> , 24, 184-188	4.6	2
22	Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	2

21	Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 705-708	3.3	1
20	Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 607-611	2.6	1
19	Calcaneal Quantitative Ultrasonography and Urinary Retinol-Binding Protein in Antiretroviral-Treated Patients With Human Immunodeficiency Virus in Uganda: A Pilot Study. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 222, 263-272	7	1
18	Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>2020</b> , 45, 405-412	2.7	1
17	Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3. <i>European Journal of Public Health</i> , <b>2017</b> , 27, 938-941	2.1	1
16	Validation and Clinical Application of a New Liquid Chromatography Coupled to Mass Spectrometry (HPLC-MS) Method for Dalbavancin Quantification in Human Plasma. <i>Separations</i> , <b>2021</b> , 8, 189	3.1	1
15	Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. <i>Blood</i> , <b>2012</b> , 120, 4903-4903	2.2	1
14	Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	1
13	The Role of IL28B Genotype in HCV-RNA Baseline Levels. <i>Intervirology</i> , <b>2016</b> , 59, 67-68	2.5	1
12	Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2019</b> , 94, 202-204	2.9	1
11	Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients. <i>Pharmacogenetics and Genomics</i> , <b>2018</b> , 28, 199-206	1.9	1
10	Preterm birth is not associated with asymptomatic/mild SARS-CoV-2 infection per se: Pre-pregnancy state is what matters. <i>PLoS ONE</i> , <b>2021</b> , 16, e0254875	3.7	1
9	Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	1
8	Seasonal Variation of Antiretroviral Drug Exposure during the Year: The Experience of 10 Years of Therapeutic Drug Monitoring. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	1
7	A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 755184	5.6	0
6	Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 701-707	2.6	0
5	A combined role for low vitamin D and low albumin circulating levels as strong predictors of worse outcome in COVID-19 patients. <i>Irish Journal of Medical Science</i> , <b>2022</b> , 1	1.9	0
4	A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy. <i>Phytomedicine</i> , <b>2022</b> , 102, 154218	6.5	0



- 3 Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes. *Therapeutic Drug Monitoring*, **2019**, 41, 254-255 3.2
- 2 Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study. *Archives of Virology*, **2021**, 166, 1125-1131 2.6
- 1 Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants. *Pharmaceuticals*, **2022**, 15, 630 5.2